Register for our free email digests:
Endo Pharmaceuticals Inc.
Division of Endo International PLC
www.endo.com/endopharma/home
Latest From Endo Pharmaceuticals Inc.
Pharma Enforcement Remains 'Priority Area' In FTC's 2021 Budget Request
US Federal Trade Commission has mainly focused in pay-for-delay cases over the past decade, but pricing strategies are an emerging area of attention; industry is paying close attention to potential enforcement in biosimilar market.
Intellipharmaceutics’ Oxycodone ER Returns To US FDA Panel Looking For Abuse-Deterrence Claim
Although abuse by intravenous route is expected to be deterred compared to immediate-release oxycodone, neither nasal nor oral abuse deterrence was demonstrated in two new human abuse potential studies, agency concludes; product has a new formulation and a new name, Aximris XR, since a 2017 AdComm.
Keeping Track: Ayvakit Approval, Keytruda Supplement, NME Submissions
The latest drug development news and highlights from our US FDA Performance Tracker.
Keytruda's Proposed Bladder Cancer Indication: Is Delaying Cystectomy Really A Benefit?
Oncologic Drugs Advisory Committee members wondered when Keytruda should be used since cystectomy can be curative and waiting could make the surgery more difficult.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Therapeutic Areas
- Cancer
- Gynecological, Urological
- Metabolic Disorders
- Neurology, Nervous System
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Endo International PLC
- Senior Management
- Contact Info
-
Endo Pharmaceuticals Inc.
Phone: (484) 216-0000
1400 Atwater Dr.
Malvern, PA 19355
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice